Back to Search
Start Over
Cystic fibrosis – Ten promising therapeutic approaches in the current era of care
- Source :
- Expert Opinion on Investigational Drugs. 29:1107-1124
- Publication Year :
- 2020
- Publisher :
- Informa UK Limited, 2020.
-
Abstract
- Cystic fibrosis (CF) is a genetic disease affecting multiple organ systems. Research and innovations in novel therapeutic agents and health care delivery have resulted in dramatic improvements in quality of life and survival for people with CF. Despite this, significant disease burden persists for many and this is compounded by disparities in treatment access and care which globally necessitates further work to improve outcomes. Because of the advent of numerous therapies which include gene-targeted modulators in parallel with specialized care delivery models, innovative efforts continue.In this review, we discuss the available data on investigational agents in clinical development and currently available treatments for CF. We also evaluate approaches to care delivery, consider treatment gaps, and propose future directions for advancement.Since the discovery of the CF gene, CFTR modulators have provided a hallmark of success, even though it was thought not previously possible. This has led to reinvigorated efforts and innovations in treatment approaches and care delivery. Numerous challenges remain because of genetic and phenotypic heterogeneity, access issues, and therapeutic costs, but the collaborative approach between stakeholders for continued innovation fuels optimism.
- Subjects :
- 0301 basic medicine
medicine.medical_specialty
Cystic Fibrosis
medicine.medical_treatment
Cystic Fibrosis Transmembrane Conductance Regulator
Disease
Cystic fibrosis
03 medical and health sciences
0302 clinical medicine
Drug Development
medicine
Animals
Humans
Lung transplantation
Pharmacology (medical)
Intensive care medicine
Organ system
Pharmacology
business.industry
Drugs, Investigational
General Medicine
medicine.disease
Precision medicine
Health care delivery
030104 developmental biology
030220 oncology & carcinogenesis
Mutation
Quality of Life
business
Subjects
Details
- ISSN :
- 17447658 and 13543784
- Volume :
- 29
- Database :
- OpenAIRE
- Journal :
- Expert Opinion on Investigational Drugs
- Accession number :
- edsair.doi.dedup.....1818bdcc881ee915fe9630728d8427e0
- Full Text :
- https://doi.org/10.1080/13543784.2020.1805733